{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:50:06Z","timestamp":1791424206839,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jvir.2024.10.008","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T06:56:44Z","timestamp":1729321004000},"page":"68-77.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of First-Line Microwave Ablation of Treatment-Naive Epidermal Growth Factor Receptor\u2013Mutated Advanced Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-8289","authenticated-orcid":false,"given":"Sheng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Xin","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Zhao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3345-1313","authenticated-orcid":false,"given":"Xiao-Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2024.10.008_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jvir.2024.10.008_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.jvir.2024.10.008_bib3","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jvir.2024.10.008_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2024.10.008_bib5","series-title":"Clinical practice guidelines in oncology. NSCLC 2023 V4","year":"2023"},{"key":"10.1016\/j.jvir.2024.10.008_bib6","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2024.10.008_bib8","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1148\/rg.25si055501","article-title":"Microwave ablation: principles and applications","volume":"25","author":"Simon","year":"2005","journal-title":"Radiographics"},{"key":"10.1016\/j.jvir.2024.10.008_bib9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00432-019-03043-6","article-title":"Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment","volume":"146","author":"Ni","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jvir.2024.10.008_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4149\/neo_2021_200506N489","article-title":"Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR\/PI3K\/AKT pathway","volume":"68","author":"Wang","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.jvir.2024.10.008_bib13","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1007\/s00330-019-06613-x","article-title":"Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial","volume":"30","author":"Wei","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jvir.2024.10.008_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib15","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer\u2014a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib16","first-page":"1241","article-title":"Society of Interventional Radiology quality improvement standards on percutaneous ablation of non-small cell lung cancer and metastatic disease to the lungs","volume":"32","author":"Genshaft","year":"2021","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2024.10.008_bib17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jvir.2014.08.027","article-title":"Image-guided tumor ablation: standardization of terminology and reporting criteria\u2014a 10-year update","volume":"25","author":"Ahmed","year":"2014","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2024.10.008_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2024.10.008_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","article-title":"EGF receptor trafficking: consequences for signaling and cancer","volume":"24","author":"Tomas","year":"2014","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.jvir.2024.10.008_bib21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2024.10.008_bib24","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2024.10.008_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in\u00a0EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2024.10.008_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.jvir.2024.10.008_bib27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/1759-7714.12779","article-title":"Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors","volume":"9","author":"Li","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jvir.2024.10.008_bib28","volume":"95","author":"Ni","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jvir.2024.10.008_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00270-018-02153-x","article-title":"Local thermal ablation with continuous EGFR tyrosine kinase inhibitors for EGFR-mutant non-small cell lung cancers that developed extra-central nervous system (CNS) oligoprogressive disease","volume":"42","author":"Ni","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2024.10.008_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrc3672","article-title":"Thermal ablation of tumours: biological mechanisms and advances in therapy","volume":"14","author":"Chu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jvir.2024.10.008_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-016-0399-7","article-title":"Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways","volume":"35","author":"Wan","year":"2016","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jvir.2024.10.008_bib32","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.athoracsur.2011.11.043","article-title":"Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence","volume":"93","author":"Lanuti","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jvir.2024.10.008_bib33","doi-asserted-by":"crossref","first-page":"56714","DOI":"10.18632\/oncotarget.18083","article-title":"Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations","volume":"8","author":"Wei","year":"2017","journal-title":"Oncotarget"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044324006432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044324006432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:56:32Z","timestamp":1791420992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044324006432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1051044324006432"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2024.10.008","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of First-Line Microwave Ablation of Treatment-Naive Epidermal Growth Factor Receptor\u2013Mutated Advanced Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2024.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2024","name":"copyright","label":"Copyright"}]}}